Fig. 2: Summary of Treatment-Emergent Adverse Events by Severity for Each of the Three Study Drugs. | npj Breast Cancer

Fig. 2: Summary of Treatment-Emergent Adverse Events by Severity for Each of the Three Study Drugs.

From: Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− breast cancer

Fig. 2

Toxicity assessment board for frequencies and grades of unique treatment-emergent adverse events for HCQ (top panels), letrozole (middle panels and palbociclib (bottom panels); Grades 1 and 2 adverse events per each drug are depicted to the right, and grades 3 and 4 adverse events per each drug are depicted to the left.

Back to article page